TNXP - Kapitalisasi marang volume dodolan Tonix Pharmaceuticals Inc.
Tonix Pharmaceuticals (TNXP) shareholder stakes are being diluted due to regular secondary offerings to fund project development. The shift in the P/S multiple reflects the business valuation dynamics, where 1.40 shapes the current metric. The company's survival depends on FDA verdicts in the CNS field, while overall success is based on scientific breakthroughs in treating infections, ignoring standard economic cycles.
Tonix Pharmaceuticals Holding Corp. (TNXP) - rincian metrik lan laporan keuangan
- rega saham lan konsensus proyeksi valuasi:
- statistik kapitalisasi pasar:
- informasi kapitalisasi buku:
- indikator beban kredit lan likuiditas emiten:
Koefisien Total Utang marang Modal Tonix Pharmaceuticals|TNXP - Rasio utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal Tonix Pharmaceuticals Holding Corp.|TNXP - Gunggung utang perusahaan|Rasio utang marang aset resik Tonix Pharmaceuticals|TNXP - Utang jangka dawa perusahaan|Kewajiban jangka cendhak Tonix Pharmaceuticals|Rasio jangkoan perantara tonixpharma.com
- data bathi lan kelipatan valuasi:
TNXP - Bathi resik|Proyeksi bathi mangsa ngarep Tonix Pharmaceuticals|TNXP - Rasio rega marang bathi|Pangali mangsa ngarep rega marang bathi Tonix Pharmaceuticals Holding|TNXP - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Tonix Pharmaceuticals Holding|TNXP - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Tonix Pharmaceuticals|TNXP - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan tonixpharma.com|TNXP - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Tonix Pharmaceuticals
- data total pendapatan lan volume dodolan:
Ringkesan analitik perusahaan:Tonix Pharma, TNXP
The P/S ratio compares market capitalization to actual sales volume, allowing for an assessment of the premium paid for future earnings. By analyzing the P/S ratio dynamics of Tonix Pharmaceuticals (TNXP), an investor can determine whether market expectations are justified within the biopharmaceutical context, where low mass-production costs following expensive clinical trials ensure high business scalability.
Pesaing Tonix Pharmaceuticals
HLN (Haleon) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Kenvue Inc KVUE|Verona Pharma Corp - Rasio rega marang pendapatan|MENS: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Rasio rega marang pendapatan|Perrigo Company PLC - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan alvotech.com|Multiplikator P/S Liquidia Technologies|Rasio rega marang pendapatan Galapagos Genomics (GLPG)|ANIP: Rasio rega marang dodolan|Multiplikator P/S MNKD (MannKind Corp)|Koefisien rega marang pendapatan Amphastar (AMPH)|PCRX: Kapitalisasi marang pendapatan|SPRY - Multiplikator P/S|Theravance Biopharma, Inc. (TBPH) - Rasio rega marang pendapatan|AQST (Aquestive Therapeutics) - Rasio rega marang pendapatan|SCPH (scpharmaceuticals.com) - Multiplikator P/S|TECX: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan SXTC (SXT Pharmaceuticals)|EPRX: Rasio rega marang dodolan|BioHarvest Sciences - Kapitalisasi marang pendapatan|EXOZ: Rasio kapitalisasi marang pendapatan|ORMP - Rasio rega marang pendapatan|ENTX: Rasio rega marang pendapatan|HYFT: Multiplikator P/S|Kapitalisasi marang pendapatan ABVC BioPharma Inc|CPIX (Cumberland Corp) - Multiplikator P/S|Multiplikator P/S quantumbiopharma.com|Multiplikator P/S FGEN|Kapitalisasi marang pendapatan Telomir Pharmaceuticals, Inc. TELO|Multiplikator P/S RANI (Rani Therapeutics)|SNYR (Synergy CHC Corp) - Rasio rega marang dodolan|RLYB: Kapitalisasi marang pendapatan|lexariabioscience.com (LEXX) - Kapitalisasi marang pendapatan|Pulmatrix Inc (PULM) - Rasio rega marang pendapatan|PTHL: Kapitalisasi marang volume dodolan|APM (Aptorum Group Ltd) - Multiplikator P/S|Lyra Therapeutics Inc (LYRA) - Koefisien rega marang pendapatan|Multiplikator P/S IBO|Kapitalisasi marang volume dodolan TNFA|cbdMD, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan PRFX|Altamira Therapeutics Ltd. - Multiplikator P/S|LIPO: Rasio rega marang pendapatan|OPTN: Multiplikator P/S|Rasio rega marang dodolan PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - Multiplikator P/S|PTPI (Petros Pharmaceuticals Inc) - Kapitalisasi marang volume dodolan|Multiplikator P/S QLI|SLRN - Rega marang dodolan|Multiplikator P/S TFFP (TFF Pharmaceuticals, Inc)
